Oral Session 3-10A CML: Clinical Study (1)

[OS3-10A-1] Interim results of a post-marketing surveillance of ponatinib

Arinobu Tojo¹, Satoshi Matsuo², Masao Hirota³, Masahiro Fujimura³, Akira Masunari², Yauhiko Fukuta², Takeshi Kondo⁴, Yoshihiro Fukumoto⁵, Naoto Takahashi⁶, Yuji Ikari⁷, Kiyohiko Hatake⁸ (1.The Institute of Medical Science, University of Tokyo, Tokyo, Japan, 2.Pharmacovigilance, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan, 3.Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, 4.Aiiku Hospital, Sapporo, Japan, 5.Kurume University, Kurume, Japan, 6.Akita University, Akita, Japan, 7.Tokai University School of Medicine, Kanagawa, Japan, 8.International University of Health and Welfare, Tokyo, Japan)